A Phase 1 interventional study of ECC5004 and Midazolam in Type 2 Diabetes Mellitus, sponsored by Eccogene. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-22.
Sponsored by Eccogene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.
Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 5 that started in 2024, is one of 11 in phase 1, and was the 3rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China, Hong Kong, Malaysia and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Bulgaria and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
AstraZeneca · Sites in United States, Bulgaria, China and 13 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 57 across the 18 interventional studies. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 2 most frequent:
Eccogene is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Eccogene has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
1 of the studies testing elecoglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07534592AstraZenecaA Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | 2027-01-25 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.
The study consists of four parts (Part A, Part B, optional Part C and optional Part D), each with approximately 16 healthy participants enrolled. Part A and optional Part C of the study will have the same study design with two treatment periods, except that ECC5004 will be administered at a higher dose level in the optional Part C. Part B and optional Part D of the study will have the same study design with five treatment periods, except that ECC5004 will be administered at a higher dose level in optional Part D. Rosuvastatin and Digoxin will be administered alone or in combination with EC5004 in Part A and optional Part C. Atorvastatin and Midazolam will be administered alone or in combination with ECC5004 in Part B and optional Part D. The conduct of Part C and Part D with an increased dose of ECC5004 may be conducted as optional parts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A consists of 2 treatment periods. Participants will receive Digoxin and Rosuvastatin administered alone in treatment period 1 and in combination with ECC5004 in treatment period 2.
Drug: ECC5004 · Drug: Rosuvastatin · Drug: Digoxin
Part B consists of 5 treatment periods. In treatment period 1, participants will receive Midazolam administered alone followed by treatment period 2 in which participants will receive Atorvastatin administered alone. In treatment period 3, participants will receive ECC5004 alone. In treatment period 4, participants will receive ECC5004 in combination with Midazolam. In treatment period 5, ECC5004 will be administered alone and co-administered with Atorvastatin.
Drug: ECC5004 · Drug: Midazolam · Drug: Atorvastatin
Optional Part C consists of 2 treatment periods. Participants will receive Digoxin and Rosuvastatin administered alone in treatment period 1 and in combination with ECC5004 in treatment period 2.
Drug: ECC5004 · Drug: Rosuvastatin · Drug: Digoxin
Optional Part D consists of 5 treatment periods. In treatment period 1, participants will receive Midazolam administered alone followed by treatment period 2 in which participants will receive Atorvastatin administered alone. In treatment period 3, participants will receive ECC5004 alone. In treatment period 4, participants will receive ECC5004 in combination with Midazolam. In treatment period 5, ECC5004 will be administered alone and co-administered with Atorvastatin.
Drug: ECC5004 · Drug: Midazolam · Drug: Atorvastatin
ECC5004 tablet will be administered orally.
Midazolam will be administered orally.
Rosuvastatin will be administered orally.
Digoxin will be administered orally.
Atorvastatin will be administered orally.
Atorvastatin PK parameters: AUC(0-tlast)
Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non Zero Concentration
Time frame: Part B and optional Part D: up to Day 34
Atorvastatin PK parameters: AUC(0-inf)
Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity
Time frame: Part B and optional Part D: up to Day 34
Atorvastatin PK parameters: Cmax
Maximum observed plasma concentration
Time frame: Part B and optional Part D: up to Day 34
Rosuvastatin PK parameters: AUC(0-tlast)
Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non Zero Concentration
Time frame: Part A and optional Part C: up to Day 11
Rosuvastatin PK parameters: AUC(0-inf)
Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity
Time frame: Part A and optional Part C: up to Day 11
Rosuvastatin PK parameters: Cmax
Maximum observed plasma concentration
Time frame: Part A and optional Part C: up to Day 11
Digoxin PK parameters: AUC(0-tlast)
Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non Zero Concentration
Time frame: Part A and optional Part C: up to Day 11
Digoxin PK parameters: AUC(0-inf)
Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity
Time frame: Part A and optional Part C: up to Day 11
Digoxin PK parameters: Cmax
Maximum observed plasma concentration
Time frame: Part A and optional Part C: up to Day 11
Midazolam PK parameters: AUC(0-tlast)
Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non Zero Concentration
Time frame: Part B and optional Part D: up to Day 34
Midazolam PK parameters: AUC(0-inf)
Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity
Time frame: Part B and optional Part D: up to Day 34
Midazolam PK parameters: Cmax
Maximum observed plasma concentration
Time frame: Part B and optional Part D: up to Day 34
ECC5004 Safety parameters: Number of participants with adverse events (AEs)
Safety Assessment evaluated through adverse events
Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40
ECC5004 Safety parameters: Number of participants with vital sign abnormalities
Safety Assessment evaluated through vital signs
Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40
ECC5004 Safety parameters: Number of participants with electrocardiogram (ECG) abnormalities
Safety Assessment evaluated through electrocardiograms (ECGs)
Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40
ECC5004 Safety parameters: Number of participants with physical examination abnormalities
Safety Assessment evaluated through physical examination
Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40
ECC5004 Safety parameters: Number of participants with clinical laboratory abnormalities
Safety Assessment evaluated through clinical laboratory assessments
Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40
Atorvastatin safety parameters: Number of participants with adverse events (AEs)
Safety Assessment evaluated through adverse events
Time frame: Part B and optional Part D: up to Day 40
Atorvastatin safety parameters: Number of participants with vital sign abnormalities
Safety Assessment evaluated through vital signs
Time frame: Part B and optional Part D: up to Day 40
Atorvastatin safety parameters: Number of participants with electrocardiogram (ECG)
Safety Assessment evaluated through electrocardiograms (ECGs)
Time frame: Part B and optional Part D: up to Day 40
Atorvastatin safety parameters: Number of participants with physical examination abnormalities
Safety Assessment evaluated through physical examination
Time frame: Part B and optional Part D: up to Day 40
Atorvastatin safety parameters: Number of participants with clinical laboratory abnormalities
Safety Assessment evaluated through clinical laboratory assessments
Time frame: Part B and optional Part D: up to Day 40
Rosuvastatin safety parameters: Number of participants with adverse events (AEs)
Safety Assessment evaluated through adverse events
Time frame: Part A and optional Part C: up to Day 16
Rosuvastatin safety parameters: Number of participants with vital sign abnormalities
Safety Assessment evaluated through vital signs
Time frame: Part A and optional Part C: up to Day 16
Rosuvastatin safety parameters: Number of participants with electrocardiogram (ECG) abnormalities
Safety Assessment evaluated through electrocardiograms (ECGs)
Time frame: Part A and optional Part C: up to Day 16
Rosuvastatin safety parameters: Number of participants with physical examination abnormalities
Safety Assessment evaluated through physical examination
Time frame: Part A and optional Part C: up to Day 16
Rosuvastatin safety parameters: Number of participants with clinical laboratory abnormalities
Safety Assessment evaluated through clinical laboratory assessments
Time frame: Part A and optional Part C: up to Day 16
Digoxin safety parameters: Number of participants with adverse events (AEs)
Safety Assessment evaluated through adverse events
Time frame: Part A and optional Part C: up to Day 16
Digoxin safety parameters: Number of participants with vital sign abnormalities
Safety Assessment evaluated through vital signs
Time frame: Part A and optional Part C: up to Day 16
Digoxin safety parameters: Number of participants with electrocardiogram (ECG) abnormalities
Safety Assessment evaluated through electrocardiograms (ECGs)
Time frame: Part A and optional Part C: up to Day 16
Digoxin safety parameters: Number of participants with physical examination abnormalities
Safety Assessment evaluated through physical examination
Time frame: Part A and optional Part C: up to Day 16
Digoxin safety parameters: Number of participants with clinical laboratory abnormalities
Safety Assessment evaluated through clinical laboratory assessments
Time frame: Part A and optional Part C: up to Day 16
Midazolam safety parameters: Number of participants with adverse events (AEs)
Safety Assessment evaluated through adverse events
Time frame: Part B and optional Part D: up to Day 40
Midazolam safety parameters: Number of participants with vital sign abnormalities
Safety Assessment evaluated through vital signs
Time frame: Part B and optional Part D: up to Day 40
Midazolam safety parameters: Number of participants with electrocardiogram (ECG) abnormalities
Safety Assessment evaluated through electrocardiograms (ECGs)
Time frame: Part B and optional Part D: up to Day 40
Midazolam safety parameters: Number of participants with physical examination abnormalities
Safety Assessment evaluated through physical examination
Time frame: Part B and optional Part D: up to Day 40
Midazolam safety parameters: Number of participants with clinical laboratory abnormalities
Safety Assessment evaluated through clinical laboratory assessments
Time frame: Part B and optional Part D: up to Day 40
ECC5004 PK parameters: AUC (0-τ)
Area under the Plasma Concentration-Time Curve during the Dosing Interval
Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34
ECC5004 PK parameters: AUC(0-24)
Area under the Plasma Concentration-Time Curve from Time 0 to 24 Hours Post-dose
Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34
ECC5004 PK parameters: tmax
Time of the maximum observed plasma concentration
Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34
ECC5004 PK parameters: t1/2
Apparent terminal elimination half-life
Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34
ECC5004 PK parameters: CL/F
Apparent Clearance
Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34
ECC5004 PK parameters: Ctau
Observed Concentration at the End of the Dosing Interval
Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Apr 2024, 2 months.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elecoglipron · Atorvastatin
Eccogene